Study of R-3750 for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests an experimental drug called R-3750 for people with active Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with Crohn's disease and had symptoms for at least 3 months.
- You have active disease, with a Harvey-Bradshaw score between 5 and 15 at screening.
- You have signs of inflammation in your body, such as high CRP or fecal calprotectin levels, or inflammation seen on a scope or biopsy.
- You are not currently in remission and do not have severe Crohn's requiring urgent treatment or surgery.
- You have not had certain infections, bowel surgery in the last 3 months, or used certain medications like biologics or antibiotics in the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This study is testing an investigational medication for moderate to severe ulcerative colitis (UC) that has not responded well to other treatments. The goal is to see if the drug can help reduce inflammation and improve symptoms.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.